TCTMD News http://www.tctmd.com/news/rss TCTMD News en Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events http://www.tctmd.com/news/diabetes-drugs-show-benefit-pad-only-mixed-results-primary-prevention-cv-events <span class="field field--name-title field--type-string field--label-hidden">Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/diabetes-drugs-show-benefit-pad-only-mixed-results-primary-prevention-cv-events"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.17.17%20Diabetes%20Drugs%20Show%20Benefit%20in%20PAD%2C%20but%20Only%20Mixed%20Results%20in%20Primary%20Prevention%20of%20CV%20Events.jpg?itok=BjYBIAA7" width="220" height="124" alt="Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 11/17/2017 - 14:31</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">One SGLT-2 inhibitor reduced the risk of MACE in PAD patients, while another had questionable effects in those without prior CVD.</div> Fri, 17 Nov 2017 19:31:41 +0000 yplata 25564 at http://www.tctmd.com EVAR Shown to IMPROVE Outcomes Over Surgery for Ruptured AAA Patients http://www.tctmd.com/news/evar-shown-improve-outcomes-over-surgery-ruptured-aaa-patients <span class="field field--name-title field--type-string field--label-hidden">EVAR Shown to IMPROVE Outcomes Over Surgery for Ruptured AAA Patients </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/evar-shown-improve-outcomes-over-surgery-ruptured-aaa-patients"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/EVAR-1%20Updated.jpg?itok=8Zkfi9K_" width="220" height="118" alt="EVAR Shown to IMPROVE Outcomes Over Surgery for Ruptured AAA Patients " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 11/17/2017 - 09:58</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Minimally-invasive repair was associated with fewer deaths, better QoL, and lower overall costs of care.</div> Fri, 17 Nov 2017 14:58:55 +0000 yplata 25563 at http://www.tctmd.com RE-DUAL PCI Findings Consistent Across Key Subgroups http://www.tctmd.com/news/re-dual-pci-findings-consistent-across-key-subgroups <span class="field field--name-title field--type-string field--label-hidden">RE-DUAL PCI Findings Consistent Across Key Subgroups</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/re-dual-pci-findings-consistent-across-key-subgroups"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/RE-DUAL%20Image%20Updated%20Header.jpg?itok=4TfdzHhh" width="220" height="117" alt="RE-DUAL PCI Findings Consistent Across Key Subgroups" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/16/2017 - 13:03</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">PCI indication, stent type, and choice of P2Y12 inhibitor did not have a significant impact on the benefits of dabigatran-based dual therapy.</div> Thu, 16 Nov 2017 18:03:29 +0000 yplata 25557 at http://www.tctmd.com Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY http://www.tctmd.com/news/sustained-blood-pressure-reductions-gastric-bypass-surgery-gateway <span class="field field--name-title field--type-string field--label-hidden">Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/sustained-blood-pressure-reductions-gastric-bypass-surgery-gateway"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.16.17.%20Sustained%20Blood%20Pressure%20Reductions%20With%20Gastric%20Bypass%20Surgery%20GATEWAY.jpg?itok=-L54JTkv" width="220" height="124" alt="Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/16/2017 - 12:43</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Twelve months after bariatric surgery, 84% had achieved a BP target of less than 140 mm Hg and more than half had a remission of hypertension </div> Thu, 16 Nov 2017 17:43:44 +0000 yplata 25556 at http://www.tctmd.com Reimbursement Remedy Backfires: Stress Tests Have Shifted From Private Practice to Hospitals, Driving Up Costs http://www.tctmd.com/news/reimbursement-remedy-backfires-stress-tests-have-shifted-private-practice-hospitals-driving <span class="field field--name-title field--type-string field--label-hidden">Reimbursement Remedy Backfires: Stress Tests Have Shifted From Private Practice to Hospitals, Driving Up Costs</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/reimbursement-remedy-backfires-stress-tests-have-shifted-private-practice-hospitals-driving"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/financial.incentives.image_.header.updated.jpg?itok=hpqyAj48" width="220" height="126" alt="Reimbursement Remedy Backfires: Stress Tests Have Shifted From Private Practice to Hospitals, Driving Up Costs" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/16/2017 - 11:07</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Decade-old financial incentives created by CMS to cut down on self-referrals and inappropriate tests have not had their desired effect.</div> Thu, 16 Nov 2017 16:07:12 +0000 yplata 25555 at http://www.tctmd.com Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma http://www.tctmd.com/news/continuing-noacs-during-device-surgery-does-not-reduce-pocket-hematoma <span class="field field--name-title field--type-string field--label-hidden">Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/continuing-noacs-during-device-surgery-does-not-reduce-pocket-hematoma"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/NOAC%20Image%20Updated.jpg?itok=BicGfo39" width="220" height="122" alt="Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/15/2017 - 15:58</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Either continued or interrupted NOACs may be reasonable depending on the clinical scenario, the researcher says.</div> Wed, 15 Nov 2017 20:58:16 +0000 yplata 25551 at http://www.tctmd.com Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding http://www.tctmd.com/news/survey-says-interventionalists-believe-public-reporting-leads-high-risk-pci-avoidance-upcoding <span class="field field--name-title field--type-string field--label-hidden">Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/survey-says-interventionalists-believe-public-reporting-leads-high-risk-pci-avoidance-upcoding"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/survey_image_header.jpg?itok=AVPaTCXC" width="220" height="122" alt="Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/15/2017 - 13:21</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">To improve PCI reporting programs, one expert suggests that unhappy doctors continue making specific, consistent recommendations to their state.</div> Wed, 15 Nov 2017 18:21:30 +0000 yplata 25549 at http://www.tctmd.com ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 http://www.tctmd.com/news/de-escalating-p2y12-inhibition-possible-acute-mi-patients-prague-18 <span class="field field--name-title field--type-string field--label-hidden">‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/de-escalating-p2y12-inhibition-possible-acute-mi-patients-prague-18"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/PRAGUE%20Image%20Updated_1.jpg?itok=VDs-AY7c" width="220" height="113" alt="‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/15/2017 - 12:42</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Switching to clopidogrel was common in acute MI patients, but the switch did not increase their risk of ischemic events, say investigators. </div> Wed, 15 Nov 2017 17:42:15 +0000 yplata 25548 at http://www.tctmd.com Accelerator-2: Streamlined Regional STEMI Care Speeds Up Treatment, Lowers Mortality http://www.tctmd.com/news/accelerator-2-streamlined-regional-stemi-care-speeds-treatment-lowers-mortality <span class="field field--name-title field--type-string field--label-hidden">Accelerator-2: Streamlined Regional STEMI Care Speeds Up Treatment, Lowers Mortality </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/accelerator-2-streamlined-regional-stemi-care-speeds-treatment-lowers-mortality"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.14.17.Accelerator-2%20Streamlined%20Regional%20STEMI%20Care%20Speeds%20Up%20Treatment%2C%20Lowers%20Mortality.jpg?itok=ypGUBYiv" width="220" height="123" alt="Accelerator-2: Streamlined Regional STEMI Care Speeds Up Treatment, Lowers Mortality " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 18:32</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">In 12 US cities, researchers made changes in how to triage STEMI patients that led to reductions in treatment delays and better outcomes. </div> Tue, 14 Nov 2017 23:32:01 +0000 yplata 25540 at http://www.tctmd.com Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery http://www.tctmd.com/news/aspirin-protective-against-early-deathmi-prior-pci-patients-undergoing-noncardiac-surgery <span class="field field--name-title field--type-string field--label-hidden">Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/aspirin-protective-against-early-deathmi-prior-pci-patients-undergoing-noncardiac-surgery"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/POISE%20IMAGE%20UPDATED_0.jpg?itok=1Yogp97t" width="220" height="112" alt="Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 17:44</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">A post hoc analysis shows that post-PCI patients, some 10 years out from their procedure, saw different results from the primary POISE-2 population. </div> Tue, 14 Nov 2017 22:44:22 +0000 yplata 25539 at http://www.tctmd.com GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS http://www.tctmd.com/news/gemini-acs-1-substudy-p2y12-inhibitor-switching-uncommon-after-acs <span class="field field--name-title field--type-string field--label-hidden">GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/gemini-acs-1-substudy-p2y12-inhibitor-switching-uncommon-after-acs"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/GEMINIS%20322.png?itok=wEl_foKe" width="220" height="109" alt="GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 17:10</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings do not support the FDA’s mandate for genotyping patients in any clinical trial where clopidogrel is used, experts say.</div> Tue, 14 Nov 2017 22:10:04 +0000 yplata 25538 at http://www.tctmd.com Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear http://www.tctmd.com/news/low-dose-rivaroxaban-plus-aspirin-lowers-some-costs-compass-full-economic-impact-unclear <span class="field field--name-title field--type-string field--label-hidden">Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/low-dose-rivaroxaban-plus-aspirin-lowers-some-costs-compass-full-economic-impact-unclear"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Rivaroxaban%20Image%20AHA%202017.jpg?itok=PU2NiHbo" width="220" height="124" alt="Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 16:34</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The ultimate value of the approach will depend on drug costs and the durability of the benefit, David Cohen says.</div> Tue, 14 Nov 2017 21:34:00 +0000 yplata 25537 at http://www.tctmd.com One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs http://www.tctmd.com/news/one-eight-us-patients-mi-or-stroke-under-age-65-are-uninsured-face-catastrophic-costs <span class="field field--name-title field--type-string field--label-hidden">One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/one-eight-us-patients-mi-or-stroke-under-age-65-are-uninsured-face-catastrophic-costs"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.14.17%20One%20in%20Eight%20US%20Patients%20With%20MI%20or%20Stroke%20Under%20Age%2065%20Are%20Uninsured%2C%20Face%20Catastrophic%20Costs.jpg?itok=nn_4LC4W" width="220" height="124" alt="One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 12:28</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">MI or stroke can mean bankruptcy for younger adults with no insurance, cautions a new study that speaks to the risks of repealing Obamacare.</div> Tue, 14 Nov 2017 17:28:12 +0000 yplata 25536 at http://www.tctmd.com Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins http://www.tctmd.com/news/missed-risk-calculators-few-young-mi-patients-were-previously-statins <span class="field field--name-title field--type-string field--label-hidden">Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/missed-risk-calculators-few-young-mi-patients-were-previously-statins"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.14.17%20Missed%20by%20Risk%20Calculators%2C%20Few%20Young%20MI%20Patients%20Were%20Previously%20on%20Statins.jpg?itok=Ix1Dtddl" width="220" height="124" alt="Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/14/2017 - 12:22</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Most patients aged 50 or below didn’t meet criteria set by current cholesterol-treatment guidelines, according to registry data.</div> Tue, 14 Nov 2017 17:22:52 +0000 yplata 25535 at http://www.tctmd.com Long-Awaited Hypertension Guidelines Released at AHA http://www.tctmd.com/news/long-awaited-hypertension-guidelines-released-aha <span class="field field--name-title field--type-string field--label-hidden">Long-Awaited Hypertension Guidelines Released at AHA</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/long-awaited-hypertension-guidelines-released-aha"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Blood%20Presure%20Image%20Header.jpg?itok=gew6k-7_" width="220" height="126" alt="Long-Awaited Hypertension Guidelines Released at AHA" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/13/2017 - 16:48</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">(UPDATED) The treatment goal has been lowered, and a new classification expands the number of US adults considered to have hypertension.</div> Mon, 13 Nov 2017 21:48:13 +0000 yplata 25530 at http://www.tctmd.com Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI http://www.tctmd.com/news/two-fourier-subgroup-analyses-show-added-benefit-evolocumab-those-pad-prior-mi <span class="field field--name-title field--type-string field--label-hidden">Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/two-fourier-subgroup-analyses-show-added-benefit-evolocumab-those-pad-prior-mi"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/FOURIER-AHA17-Tier%202%2011.3.17.jpg?itok=RL7IYVYS" width="220" height="128" alt="Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/13/2017 - 16:15</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings may help physicians target the use of PCSK9 inhibitors to the patients who will benefit the most, one expert said.</div> Mon, 13 Nov 2017 21:15:28 +0000 yplata 25529 at http://www.tctmd.com CANTOS: Big Drop in CVD Events Among Canakinumab Responders http://www.tctmd.com/news/cantos-big-drop-cvd-events-among-canakinumab-responders <span class="field field--name-title field--type-string field--label-hidden">CANTOS: Big Drop in CVD Events Among Canakinumab Responders</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/cantos-big-drop-cvd-events-among-canakinumab-responders"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/CANTOS%20AHA%20Image%20Header%20Sharpen.jpg?itok=PeIA-W7b" width="220" height="126" alt="CANTOS: Big Drop in CVD Events Among Canakinumab Responders" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/13/2017 - 14:24</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">(UPDATED) The analysis identified “biologic responders” to therapy, suggesting a single dose might be used to determine who would benefit.</div> Mon, 13 Nov 2017 19:24:52 +0000 yplata 25528 at http://www.tctmd.com Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation http://www.tctmd.com/news/angiography-revascularization-safe-acute-mi-patients-taking-oacs-atrial-fibrillation <span class="field field--name-title field--type-string field--label-hidden">Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/angiography-revascularization-safe-acute-mi-patients-taking-oacs-atrial-fibrillation"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.13.17.Angiography%2C%20Revascularization%20Safe%20in%20Acute%20MI%20Patients%20Taking%20OACs%20for%20Atrial%20Fibrillation.jpg?itok=T0eNIgxY" width="220" height="113" alt="Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/13/2017 - 13:52</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Compared with no use of oral anticoagulants, warfarin and DOAC use did not increase the risk of bleeding in patients with NSTEMI or STEMI. </div> Mon, 13 Nov 2017 18:52:01 +0000 yplata 25527 at http://www.tctmd.com TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery http://www.tctmd.com/news/trics-iii-restrictive-red-cell-transfusion-noninferior-liberal-use-cardiac-surgery <span class="field field--name-title field--type-string field--label-hidden">TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/trics-iii-restrictive-red-cell-transfusion-noninferior-liberal-use-cardiac-surgery"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Image.%20TRICS%20III%20Restrictive%20Red-Cell%20Transfusion%20Noninferior%20to%20Liberal%20Use%20in%20Cardiac%20Surgery_0.jpg?itok=g8_NuMDM" width="220" height="131" alt="TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 18:33</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The study should reassure hospitals and clinicians that have already adopted restricted transfusion protocols, even in older patients.</div> Sun, 12 Nov 2017 23:33:51 +0000 yplata 25524 at http://www.tctmd.com DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy http://www.tctmd.com/news/dacab-ticagrelor-and-aspirin-improve-svg-patency-1-year-post-cabg-vs-monotherapy <span class="field field--name-title field--type-string field--label-hidden">DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/dacab-ticagrelor-and-aspirin-improve-svg-patency-1-year-post-cabg-vs-monotherapy"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.12.17.DACAB%20Ticagrelor%20and%20Aspirin%20Improve%20SVG%20Patency%20at%201%20Year%20Post-CABG%20vs%20Monotherapy_0.jpg?itok=8P3pO1TQ" width="220" height="128" alt="DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 18:38</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Notably, most patients received off-pump CABG, which may affect the need for anticoagulation compared with cardiopulmonary bypass.</div> Sun, 12 Nov 2017 23:38:57 +0000 yplata 25525 at http://www.tctmd.com PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI http://www.tctmd.com/news/preserve-puts-kibosh-approaches-preventing-contrast-associated-aki <span class="field field--name-title field--type-string field--label-hidden">PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/preserve-puts-kibosh-approaches-preventing-contrast-associated-aki"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/PRESERVE%20updated%20image.jpg?itok=UIxAJK4H" width="220" height="125" alt="PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 18:44</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">No major surprise: IV sodium bicarbonate and oral N-acetylcysteine were no help in thwarting the complication following angiography.</div> Sun, 12 Nov 2017 23:44:24 +0000 yplata 25526 at http://www.tctmd.com Big BP Reductions When DASH Diet Combined With Low Sodium Intake http://www.tctmd.com/news/big-bp-reductions-when-dash-diet-combined-low-sodium-intake <span class="field field--name-title field--type-string field--label-hidden">Big BP Reductions When DASH Diet Combined With Low Sodium Intake</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/big-bp-reductions-when-dash-diet-combined-low-sodium-intake"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/DASH%20diet%20story%20Updated.jpg?itok=NUefpZhS" width="220" height="118" alt="Big BP Reductions When DASH Diet Combined With Low Sodium Intake" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 17:46</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The largest decrease in systolic blood pressure was seen in the group with the most to gain, that being individuals with stage 1 hypertension.</div> Sun, 12 Nov 2017 22:46:16 +0000 yplata 25523 at http://www.tctmd.com Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List http://www.tctmd.com/news/circling-back-orbita-sham-controlled-pci-trial-makes-best-2017-list <span class="field field--name-title field--type-string field--label-hidden">Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/circling-back-orbita-sham-controlled-pci-trial-makes-best-2017-list"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.12.17.Circling%20Back%20on%20ORBITA%20Sham%20Controlled%20PCI%20Trial%20Makes%20Best%20of%202017%20List_0.jpg?itok=bnlOEpEU" width="220" height="110" alt="Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 17:25</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Several trials made the crowdsourced list, but ORBITA remains, by far, one of the most controversial and heatedly debated studies in a long time. </div> Sun, 12 Nov 2017 22:25:38 +0000 yplata 25522 at http://www.tctmd.com Better PCI Outcomes Not Guaranteed at Top-Ranked Hospitals http://www.tctmd.com/news/better-pci-outcomes-not-guaranteed-top-ranked-hospitals <span class="field field--name-title field--type-string field--label-hidden">Better PCI Outcomes Not Guaranteed at Top-Ranked Hospitals </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/better-pci-outcomes-not-guaranteed-top-ranked-hospitals"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.12.17.Better%20PCI%20Outcomes%20Not%20Guaranteed%20at%20Top-Ranked%20Hospitals_0.jpg?itok=6nOiSIlM" width="220" height="117" alt="Better PCI Outcomes Not Guaranteed at Top-Ranked Hospitals " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 16:53</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">But there’s also good news: safe and appropriate PCI is being performed at many hospitals throughout the country.</div> Sun, 12 Nov 2017 21:53:12 +0000 yplata 25521 at http://www.tctmd.com Getting It On? Carry On: Sudden Cardiac Arrest Risk Low With Sexual Activity http://www.tctmd.com/news/getting-it-carry-sudden-cardiac-arrest-risk-low-sexual-activity <span class="field field--name-title field--type-string field--label-hidden">Getting It On? Carry On: Sudden Cardiac Arrest Risk Low With Sexual Activity</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/getting-it-carry-sudden-cardiac-arrest-risk-low-sexual-activity"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/SexCardiacDeath.jpg?itok=JGbsn0dL" width="220" height="118" alt="Getting It On? Carry On: Sudden Cardiac Arrest Risk Low With Sexual Activity" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sun, 11/12/2017 - 12:18</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Researchers say the findings have educational implications for physicians fielding questions from worried patients. </div> Sun, 12 Nov 2017 17:18:05 +0000 yplata 25520 at http://www.tctmd.com Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many http://www.tctmd.com/news/low-high-sensitivity-troponin-i-cutoff-may-allow-discharge-ed-many <span class="field field--name-title field--type-string field--label-hidden">Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/low-high-sensitivity-troponin-i-cutoff-may-allow-discharge-ed-many"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Troponin%20story.jpg?itok=g0aLNdq0" width="220" height="127" alt="Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13826" typeof="schema:Person" property="schema:name" datatype="">sgutch</span></span> <span class="field field--name-created field--type-created field--label-hidden">Sat, 11/11/2017 - 16:45</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Nearly half of patients had levels below 5 ng/L at presentation, and the rate of MI or cardiac death at 30 days was very low in this group.</div> Sat, 11 Nov 2017 21:45:36 +0000 sgutch 25519 at http://www.tctmd.com Valve-in-Ring, Valve-in-MAC TMVR Procedures Feasible, but Patient Selection Is Key http://www.tctmd.com/news/valve-ring-valve-mac-tmvr-procedures-feasible-patient-selection-key <span class="field field--name-title field--type-string field--label-hidden">Valve-in-Ring, Valve-in-MAC TMVR Procedures Feasible, but Patient Selection Is Key</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/valve-ring-valve-mac-tmvr-procedures-feasible-patient-selection-key"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/MAYRA%20GUERRERO-0072%20Updated.jpg?itok=sYGKETa3" width="220" height="125" alt="Valve-in-Ring, Valve-in-MAC TMVR Procedures Feasible, but Patient Selection Is Key" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 11/10/2017 - 09:58</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">For patients at too high of a risk for surgery, TMVR could provide a reasonable alternative, experts say.</div> Fri, 10 Nov 2017 14:58:05 +0000 yplata 25518 at http://www.tctmd.com Transradial Access in Primary PCI on the Upswing in the US but Still Uneven http://www.tctmd.com/news/transradial-access-primary-pci-upswing-us-still-uneven <span class="field field--name-title field--type-string field--label-hidden">Transradial Access in Primary PCI on the Upswing in the US but Still Uneven</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/transradial-access-primary-pci-upswing-us-still-uneven"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.10.17.Transradial%20Access%20in%20Primary%20PCI%20on%20the%20Upswing%20in%20the%20US%20but%20Still%20Uneven.jpg?itok=D4oY0N0N" width="220" height="126" alt="Transradial Access in Primary PCI on the Upswing in the US but Still Uneven" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 11/10/2017 - 09:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/caitlin-e-cox" hreflang="en">Caitlin E. Cox</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Operator and institutional factors weigh more heavily than patient characteristics, with less radial tied to more mortality and bleeding events.</div> Fri, 10 Nov 2017 14:51:59 +0000 yplata 25517 at http://www.tctmd.com AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More http://www.tctmd.com/news/aha-2017-new-hypertension-guidelines-compass-costs-dual-drug-dilemmas-and-more <span class="field field--name-title field--type-string field--label-hidden">AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/aha-2017-new-hypertension-guidelines-compass-costs-dual-drug-dilemmas-and-more"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/AHA%20Preview%20Story%20Image%20Updated.jpg?itok=CAV6U07z" width="220" height="115" alt="AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/09/2017 - 16:30</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">In this year’s program: a whopping 33 late breakers, plus the much-anticipated release of joint guidelines for the treatment of high BP.</div> Thu, 09 Nov 2017 21:30:28 +0000 yplata 25516 at http://www.tctmd.com Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock http://www.tctmd.com/news/selection-bias-debate-asks-how-many-tavr-devices-centers-should-stock <span class="field field--name-title field--type-string field--label-hidden">Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/selection-bias-debate-asks-how-many-tavr-devices-centers-should-stock"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/11.9.17.Selection%20Bias%20Debate%20Asks%20How%20Many%20TAVR%20Devices%20Centers%20Should%20Stock.jpg?itok=YGAkmn6N" width="220" height="124" alt="Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/09/2017 - 13:46</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Most interventionalists agree that operators should have access to at least two valves, but as a recent debate concluded, volume matters.</div> Thu, 09 Nov 2017 18:46:28 +0000 yplata 25514 at http://www.tctmd.com Experts Debate: Should Cerebral Protection Be Used for All TAVRs? http://www.tctmd.com/news/experts-debate-should-cerebral-protection-be-used-all-tavrs <span class="field field--name-title field--type-string field--label-hidden">Experts Debate: Should Cerebral Protection Be Used for All TAVRs?</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/experts-debate-should-cerebral-protection-be-used-all-tavrs"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/CerebralProtection%20Updated.png?itok=Y9L31KNz" width="220" height="121" alt="Experts Debate: Should Cerebral Protection Be Used for All TAVRs?" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/09/2017 - 09:44</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Saif Anwaruddin says all patients should be protected, but Duane Pinto argues that the evidence supports a more selective approach.</div> Thu, 09 Nov 2017 14:44:16 +0000 yplata 25508 at http://www.tctmd.com Positionable Shields Slash Radiation Exposure to Cath Lab Staff by Two-Thirds http://www.tctmd.com/news/positionable-shields-slash-radiation-exposure-cath-lab-staff-two-thirds <span class="field field--name-title field--type-string field--label-hidden">Positionable Shields Slash Radiation Exposure to Cath Lab Staff by Two-Thirds</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/positionable-shields-slash-radiation-exposure-cath-lab-staff-two-thirds"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Image.%20Positionable%20Shields%20Slash%20Radiation%20Exposure%20to%20Cath%20Lab%20Staff%20by%20Two-Thirds.jpg?itok=kJ-ZEtlO" width="220" height="129" alt="Positionable Shields Slash Radiation Exposure to Cath Lab Staff by Two-Thirds" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/08/2017 - 17:02</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The findings may be particularly relevant for nurse circulators, who spend more cumulative time in procedures than physicians do.</div> Wed, 08 Nov 2017 22:02:37 +0000 yplata 25504 at http://www.tctmd.com TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG http://www.tctmd.com/news/tavr-beats-out-savr-least-hospital-patients-prior-cabg <span class="field field--name-title field--type-string field--label-hidden">TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/tavr-beats-out-savr-least-hospital-patients-prior-cabg"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Image.%20TAVR%20Beats%20Out%20SAVR%2C%20at%20Least%20In-Hospital%2C%20for%20Patients%20With%20Prior%20CABG_0.jpg?itok=plHBVgT7" width="220" height="123" alt="TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/08/2017 - 15:49</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/ashley-lyles" hreflang="en">Ashley Lyles</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Prior CABG may actually put patients at higher surgical risk, one expert speculates, making TAVR the better option in this group.</div> Wed, 08 Nov 2017 20:49:06 +0000 yplata 25503 at http://www.tctmd.com A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients http://www.tctmd.com/news/fib-signals-worse-prognosis-after-aortic-valve-replacement-intermediate-risk-patients <span class="field field--name-title field--type-string field--label-hidden">A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/fib-signals-worse-prognosis-after-aortic-valve-replacement-intermediate-risk-patients"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Image.%20A-fib%20Signals%20Worse%20Prognosis%20After%20Aortic%20Valve%20Replacement%20in%20Intermediate-Risk%20Patients.jpg?itok=vAt26Ip9" width="220" height="123" alt="A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/08/2017 - 09:48</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Patients who have A-fib detected before or after transcatheter or surgical valve replacement are more likely to die in the next few years.</div> Wed, 08 Nov 2017 14:48:25 +0000 yplata 25500 at http://www.tctmd.com CrossBoss First Shows Promise for Antegrade CTO PCI http://www.tctmd.com/news/crossboss-first-shows-promise-antegrade-cto-pci <span class="field field--name-title field--type-string field--label-hidden">CrossBoss First Shows Promise for Antegrade CTO PCI</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/crossboss-first-shows-promise-antegrade-cto-pci"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/EMMANOUIL-BRILAKIS-0855%20UPDATED.jpg?itok=in6No8EY" width="220" height="128" alt="CrossBoss First Shows Promise for Antegrade CTO PCI" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/07/2017 - 14:50</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/tct-daily-staff" hreflang="en">TCT Daily Staff</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The small study compared use of a dedicated catheter for antegrade CTO crossing with a standard wire escalation strategy.</div> Tue, 07 Nov 2017 19:50:00 +0000 yplata 25486 at http://www.tctmd.com Early Pilot Study Results Show Symptom Improvement With TMVR http://www.tctmd.com/news/early-pilot-study-results-show-symptom-improvement-tmvr <span class="field field--name-title field--type-string field--label-hidden">Early Pilot Study Results Show Symptom Improvement With TMVR</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/early-pilot-study-results-show-symptom-improvement-tmvr"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Intrepid%20Image%20Updated.png?itok=_irFZ1-N" width="220" height="104" alt="Early Pilot Study Results Show Symptom Improvement With TMVR" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 11/07/2017 - 12:59</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">It’s early days, say experts. For TMVR to take off, research will need to show better survival and improvements in other hard clinical outcomes. </div> Tue, 07 Nov 2017 17:59:22 +0000 yplata 25485 at http://www.tctmd.com Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians http://www.tctmd.com/news/massive-study-offers-snapshot-pci-outcomes-nonagenarians <span class="field field--name-title field--type-string field--label-hidden">Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/massive-study-offers-snapshot-pci-outcomes-nonagenarians"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/old.patient.image_.jpg?itok=HZCuJooX" width="220" height="128" alt="Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/06/2017 - 09:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/ashley-lyles" hreflang="en">Ashley Lyles</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Researchers say their study should serve as a reminder that PCI carries important benefits, even in patients nearing their tenth decade of life</div> Mon, 06 Nov 2017 14:51:19 +0000 yplata 25484 at http://www.tctmd.com MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months http://www.tctmd.com/news/maveric-transcatheter-mv-repair-shows-continued-efficacy-safety-6-months <span class="field field--name-title field--type-string field--label-hidden">MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/maveric-transcatheter-mv-repair-shows-continued-efficacy-safety-6-months"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/MAVERIC%20UDPATED.png?itok=wjpOU8bH" width="220" height="122" alt="Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 11/06/2017 - 09:45</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/tct-daily-staff" hreflang="en">TCT Daily Staff</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Interest in transcatheter MV replacement, repair shows no signs of slowing down.</div> Mon, 06 Nov 2017 14:45:11 +0000 yplata 25483 at http://www.tctmd.com Quantitative Flow Ratio Shows Potential in Cath Lab http://www.tctmd.com/news/quantitative-flow-ratio-shows-potential-cath-lab <span class="field field--name-title field--type-string field--label-hidden">Quantitative Flow Ratio Shows Potential in Cath Lab</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/quantitative-flow-ratio-shows-potential-cath-lab"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/FAVOR%202%20UPDATED.jpg?itok=fvV-WRGD" width="220" height="135" alt="Quantitative Flow Ratio Shows Potential in Cath Lab" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 11/03/2017 - 14:05</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/tct-daily-staff" hreflang="en">TCT Daily Staff</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The FAVOR II studies open the door to an angiography-based strategy of assessing hemodynamically significant stenosis.</div> Fri, 03 Nov 2017 18:05:07 +0000 yplata 25482 at http://www.tctmd.com FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost http://www.tctmd.com/news/fame-2-3-years-outcomes-symptoms-better-pci-vs-omt-stable-cad-similar-cost <span class="field field--name-title field--type-string field--label-hidden">FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/fame-2-3-years-outcomes-symptoms-better-pci-vs-omt-stable-cad-similar-cost"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/WILLIAM-FEARON-FAME2%20Study%20UPDATED_0.jpg?itok=NyVRy7yZ" width="220" height="121" alt="FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/02/2017 - 15:38</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/la-mckeown" hreflang="en">L.A. McKeown</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The study found strikingly fewer urgent revascularizations and numerically fewer deaths and MIs in the PCI group when FFR was gatekeeper.</div> Thu, 02 Nov 2017 19:38:12 +0000 yplata 25481 at http://www.tctmd.com Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used http://www.tctmd.com/news/longer-term-outcomes-watchman-reassure-debate-continues-over-how-it-should-be-used <span class="field field--name-title field--type-string field--label-hidden">Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/longer-term-outcomes-watchman-reassure-debate-continues-over-how-it-should-be-used"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/SAIBAL%20KAR-PREVAIL%20study%20UDPATED.jpg?itok=sE8AjOo-" width="220" height="127" alt="Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/02/2017 - 15:24</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Lingering questions about the potential for residual ischemic stroke risk with the LAA closure device temper enthusiasm for its use.</div> Thu, 02 Nov 2017 19:24:39 +0000 yplata 25480 at http://www.tctmd.com For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results http://www.tctmd.com/news/torrential-tricuspid-regurgitation-two-new-transcatheter-devices-safe-effective-early-results <span class="field field--name-title field--type-string field--label-hidden">For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/torrential-tricuspid-regurgitation-two-new-transcatheter-devices-safe-effective-early-results"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/FORMA%20image%20UDPATED_0.jpg?itok=FsWCHcPV" width="220" height="128" alt="For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/02/2017 - 14:51</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">These patients, in the past, have had few treatment options, which is explains the excitement around new technologies in this space, experts said. </div> Thu, 02 Nov 2017 18:51:50 +0000 yplata 25479 at http://www.tctmd.com Live From Denver: TCT 2017, Day Four http://www.tctmd.com/news/live-denver-tct-2017-day-four <span class="field field--name-title field--type-string field--label-hidden">Live From Denver: TCT 2017, Day Four</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/live-denver-tct-2017-day-four"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Live%20Blog%20TCT%202017.jpg?itok=RjgfxuZQ" width="220" height="127" alt="Live From Denver: TCT 2017, Day Four" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/02/2017 - 11:47</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">This blog aims to capture headline news, as it breaks, plus random tidbits from the ground at TCT 2017. It will be updated throughout the day.</div> Thu, 02 Nov 2017 15:47:02 +0000 yplata 25461 at http://www.tctmd.com ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure http://www.tctmd.com/news/orbita-pci-offers-no-symptom-improvement-over-sham-procedure <span class="field field--name-title field--type-string field--label-hidden">ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/orbita-pci-offers-no-symptom-improvement-over-sham-procedure"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/RASHA%20Al-LAMEE-ORBITA%20study%20UPDATED.jpg?itok=ZPF8upEx" width="220" height="130" alt="ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 11/02/2017 - 14:33</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">The intriguing study, which hints at a placebo effect of PCI, left physicians debating the merits of revascularization in stable coronary artery disease.</div> Thu, 02 Nov 2017 18:33:21 +0000 yplata 25478 at http://www.tctmd.com Off Script: Connecting and Collaborating in the Global Village of Interventional Cardiology http://www.tctmd.com/news/script-connecting-and-collaborating-global-village-interventional-cardiology <span class="field field--name-title field--type-string field--label-hidden">Off Script: Connecting and Collaborating in the Global Village of Interventional Cardiology</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 19:53</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/kwan-s-lee" hreflang="en">Kwan S. Lee </a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">We as cardiologists increasingly link up in the hyper-connected world of Twitter and Facebook: we must understand the new rules of engagement.</div> Wed, 01 Nov 2017 23:53:37 +0000 yplata 25298 at http://www.tctmd.com Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES http://www.tctmd.com/news/shortened-dapt-durations-appear-safe-patients-acs-implanted-des <span class="field field--name-title field--type-string field--label-hidden">Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/shortened-dapt-durations-appear-safe-patients-acs-implanted-des"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/ELVIN-KEDHI-0001%20UPDATED.jpg?itok=g7-OD7U_" width="220" height="123" alt="Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 16:11</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">DAPT-STEMI and REDUCE found 3 and 6 months of DAPT, respectively, were noninferior to the standard 12 months of treatment.</div> Wed, 01 Nov 2017 20:11:50 +0000 yplata 25097 at http://www.tctmd.com DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients http://www.tctmd.com/news/des-bioresorbable-polymer-outperforms-bms-senior-patients <span class="field field--name-title field--type-string field--label-hidden">DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients </span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/des-bioresorbable-polymer-outperforms-bms-senior-patients"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/OLIVIER-VARENNE-1037%20%28002%29%20UDPATED.jpg?itok=63WLtz2Q" width="220" height="121" alt="DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients " typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 14:58</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/michael-oriordan" hreflang="en">Michael O&#039;Riordan</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">A chorus of interventionalists all agreed that BMS has an extremely limited role, if any, in clinical practice following results of several studies. </div> Wed, 01 Nov 2017 18:58:55 +0000 yplata 25051 at http://www.tctmd.com RECAP: In the Cath Lab, a Lead-Free Pad Placed on the Patient Cuts Operator Radiation Exposure http://www.tctmd.com/news/recap-cath-lab-lead-free-pad-placed-patient-cuts-operator-radiation-exposure <span class="field field--name-title field--type-string field--label-hidden">RECAP: In the Cath Lab, a Lead-Free Pad Placed on the Patient Cuts Operator Radiation Exposure</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/recap-cath-lab-lead-free-pad-placed-patient-cuts-operator-radiation-exposure"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/Image.RECAP_.jpg?itok=j8XK1A3p" width="220" height="125" alt="RECAP: In the Cath Lab, a Lead-Free Pad Placed on the Patient Cuts Operator Radiation Exposure" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 12:28</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/todd-neale" hreflang="en">Todd Neale</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">This is an important, rigorously conducted study in an area that is sorely in need of good data, Sunil Rao says.</div> Wed, 01 Nov 2017 16:28:21 +0000 yplata 24990 at http://www.tctmd.com Live From Denver: TCT 2017, Day Three http://www.tctmd.com/news/live-denver-tct-2017-day-three <span class="field field--name-title field--type-string field--label-hidden">Live From Denver: TCT 2017, Day Three</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/live-denver-tct-2017-day-three"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/OLIVIER-VARENNE-2-2.jpg?itok=u1q5P8Ub" width="220" height="125" alt="Live From Denver: TCT 2017, Day Three" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 13:25</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/shelley-wood" hreflang="en">Shelley Wood</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">This blog aims to capture headline news, as it breaks, plus random tidbits from the ground at TCT 2017. It will be updated throughout the day.</div> Wed, 01 Nov 2017 17:25:25 +0000 yplata 24992 at http://www.tctmd.com TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months http://www.tctmd.com/news/tracer-novel-device-effective-reducing-severe-degenerative-mr-over-6-months <span class="field field--name-title field--type-string field--label-hidden">TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months</span> <div class="field field--name-field-header-image field--type-image field--label-hidden field__item"> <a href="/news/tracer-novel-device-effective-reducing-severe-degenerative-mr-over-6-months"><img src="/sites/default/files/efs/public/styles/medium/public/2017-11/JAMES%20GAMMIE-0169%20%20UPDATED.jpg?itok=g_HklyLV" width="220" height="123" alt="TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months" typeof="foaf:Image" class="image-style-medium" /> </a> </div> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/13825" typeof="schema:Person" property="schema:name" datatype="">yplata</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 11/01/2017 - 14:32</span> <div class="field field--name-field-author field--type-entity-reference field--label-hidden"> <a href="/staff/yael-l-maxwell" hreflang="en">Yael L. Maxwell</a> </div> <div class="field field--name-field-teaser field--type-string-long field--label-hidden field__item">Though long-term data are still outstanding and procedural lessons are still being learned, the device’s inventor expects good efficacy and durability.</div> Wed, 01 Nov 2017 18:32:53 +0000 yplata 25050 at http://www.tctmd.com